Abstract Body

Background: In those experiencing virologic failure (VF) on first-line antiretroviral therapy (ART), the impact of the initial drug regimen on the rate of subsequent virologic suppression (VS) is unknown. Methodology: We describe the outcomes of second-line therapy in those experiencing VF in the AIDS Clinical Trials Group A5202 trial, a randomized study comparing tenofovir/emtricitabine or abacavir/lamivudine with either efavirenz or atazanavir and ritonavir in treatment-naive individuals. Following VF, subjects underwent resistance testing and were managed according to standard-of-care at the study sites. Subjects’ first-line regimen was defined as that taken at VF and was categorized as containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r). Subjects were classified as not taking ART at VF if they had not been on therapy for ≥ 8 weeks at the time of VF. VS on second-line ART was defined as an HIV RNA < 200 copies/mL at 24 weeks following confirmed VF. We compared VS between those who failed NNRTI- versus PI/r-based therapy using a Fisher’s exact test and a logistic regression model adjusting for age, sex, and HIV RNA, CD4 count, and resistance at VF, limiting the analysis to subjects with complete follow-up data. Results: Of 1,857 subjects, 269 (14.5%) experienced VF; 94 (34.9%) and 134 (49.8%) failed their NNRTI- or PI/r-based first-line regimens, respectively, and 41(15.2%) were not taking antiretrovirals at VF. Of subjects with genotype data at VF, resistance was detected in 71 of 92 (77.2%) failing NNRTI, 21 of 133 (15.8%) failing PI/r, and 17 of 41 (41.5%) not on ART. Therapy modifications following VF are shown in the table. At 24 weeks after confirmed VF, 141 of 155 (91.0%) subjects who had failed first-line NNRTI or PI/r therapy remained in the study on ART and had HIV RNA values available. VS was achieved on second-line ART in 42 of 56 (75.0%) subjects failing NNRTI and in 55 of 85 (64.7%) failing PI/r (unadjusted P=0.265, adjusted P=0.602); in a missing=failure sensitivity analysis, 44.7% failing NNRTI and 41.0% failing PI/r achieved VS (unadjusted P=0.590, adjusted P=0.741). Conclusions: Among those with follow-up data, therapy was changed more often following failure of NNRTI- versus PI/r-based first-line regimens, likely due to increased resistance. However, subsequent virologic suppression on second-line ART at 24 weeks did not differ significantly between the initial drug regimens.